COMP <GO>
MRVI vs PRGO // EV/EBITDA & P/E VALUATION
Maravai LifeSciences Holdings Inc. (Class A) (NASDAQ) VS. Perrigo Company plc (NYSE) • 15-METRIC TALLY: MRVI 1
— PRGO 10
■ METRIC PARITY
LAST: $8.46 (-0.47%) • MKT CAP: $2.20B
valuation
—
LAST: $15.90 (-0.13%) • MKT CAP: $2.21B
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MRVI VS. PRGO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MRVI | PRGO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 18.30% | 35.10% | -16.80 | PRGO | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -13.60% | -21.40 | PRGO | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -3.22% | 6.58% | -9.80 | PRGO | /fcf-yield <GO> |
| Operating Margin | -60.00% | -26.40% | -33.60 | PRGO | /operating-margins <GO> |
| Net Profit Margin | -60.00% | -33.50% | -26.50 | PRGO | /net-margins <GO> |
| Revenue Growth (YoY) | -28.30% | -2.80% | -25.50 | PRGO | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 7.22% | -7.22 | PRGO | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.04 | 0.20 | +2.84 | MRVI | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 5/9 | -2.00 | PRGO | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 53.6 | 55.3 | -1.69 | PRGO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.20B | $2.21B | -$9.6M | PRGO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MRVI REV | PRGO REV | MRVI GROSS % | PRGO GROSS % | MRVI FCF | PRGO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $185.7M | $4.25B | 18.3% | 35.1% | -$70.7M | $145.1M |
| FY 2024 | $259.2M | $4.37B | 41.8% | 35.3% | -$22.2M | $244.6M |
| FY 2023 | $288.9M | $4.66B | — | — | $126.2M | $405.5M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MRVI // BETA —
PRGO // BETA —